End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1.49 USD | +0.68% | +0.68% | -57.18% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 2.64M 2.94M |
---|---|---|---|---|---|
Net income 2024 * | -7M -7.8M | Net income 2025 * | -10M -11.14M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.3
x | P/E ratio 2025 * |
-0.41
x | Employees | 10 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.11% |
Latest transcript on Altamira Therapeutics Ltd.
1 day | +0.68% | ||
1 week | +0.68% | ||
Current month | -2.61% | ||
1 month | +2.76% | ||
3 months | -21.16% | ||
6 months | -60.67% | ||
Current year | -57.18% |
Managers | Title | Age | Since |
---|---|---|---|
Thomas Meyer
CEO | Chief Executive Officer | 56 | 03-03-31 |
Marcel Gremaud
DFI | Director of Finance/CFO | 66 | 21-10-31 |
Covadonga Pañeda
COO | Chief Operating Officer | 51 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Alain Munoz
BRD | Director/Board Member | 75 | 18-02-28 |
Mats Blom
BRD | Director/Board Member | 59 | 17-03-31 |
Thomas Meyer
CEO | Chief Executive Officer | 56 | 03-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-11 | 1.31 | -2.96% | 95,645 |
24-06-10 | 1.35 | -5.59% | 61,539 |
24-06-07 | 1.43 | -4.03% | 70,369 |
24-06-06 | 1.49 | 0.00% | 41,509 |
24-06-05 | 1.49 | +0.68% | 43,945 |
End-of-day quote Nasdaq, June 04, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-57.18% | 3.02M | |
+18.34% | 125B | |
+15.06% | 108B | |
-6.39% | 23.64B | |
+2.39% | 22.39B | |
-12.11% | 17.78B | |
-41.64% | 16.43B | |
-12.07% | 16.34B | |
+1.05% | 13.56B | |
+25.87% | 11.59B |
- Stock Market
- Equities
- CYTO Stock